These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 20851319)

  • 1. Cost-effectiveness of screening for and treating albuminuria in individuals without diabetes or hypertension: are we moving beyond the evidence?
    Mangione F; Esposito C; Dal Canton A
    Am J Kidney Dis; 2010 Oct; 56(4):801; author reply 801-2. PubMed ID: 20851319
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening, monitoring, and treatment of albuminuria: Public health perspectives.
    de Jong PE; Curhan GC
    J Am Soc Nephrol; 2006 Aug; 17(8):2120-6. PubMed ID: 16825331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A health policy model of CKD: 2. The cost-effectiveness of microalbuminuria screening.
    Hoerger TJ; Wittenborn JS; Segel JE; Burrows NR; Imai K; Eggers P; Pavkov ME; Jordan R; Hailpern SM; Schoolwerth AC; Williams DE;
    Am J Kidney Dis; 2010 Mar; 55(3):463-73. PubMed ID: 20116910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors.
    Golan L; Birkmeyer JD; Welch HG
    Ann Intern Med; 1999 Nov; 131(9):660-7. PubMed ID: 10577328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are we ready to screen the general population for microalbuminuria?
    Fried L
    J Am Soc Nephrol; 2009 Apr; 20(4):686-8. PubMed ID: 19279125
    [No Abstract]   [Full Text] [Related]  

  • 7. Microalbuminuria as a target to improve cardiovascular and renal outcomes.
    Basi S; Lewis JB
    Am J Kidney Dis; 2006 Jun; 47(6):927-46. PubMed ID: 16731288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preserving the diabetic kidney.
    Poirier SJ
    J Fam Pract; 1998 Jan; 46(1):21-7. PubMed ID: 9451365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical inquiries. Angiotensin blockade for diabetes: monitor microalbuminuria?
    Muench J; Blenning C; Judkins DZ; Vincent C
    J Fam Pract; 2007 Feb; 56(2):145-6. PubMed ID: 17270123
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
    Adarkwah CC; Gandjour A
    Int J Technol Assess Health Care; 2010 Jan; 26(1):62-70. PubMed ID: 20059782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The significance of diagnosing microalbuminuria and microglobulinuria in diabetes mellitus and arterial hypertension].
    Kasprowicz B; Jaremin B; Górski J
    Przegl Lek; 1997; 54(3):180-4. PubMed ID: 9297195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Subclinical albuminuria, microalbuminuria and proteinuria--accepted cardiovascular risk markers?].
    Schmieder RE; Schrader J; Zidek W; Tebbe U; Bramlage P; Paar WD; Böhm M
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2665-71. PubMed ID: 17109277
    [No Abstract]   [Full Text] [Related]  

  • 13. Practical problems in the management of hypertension in the diabetic patient.
    O'Hare JP
    J Diabetes Complications; 1996; 10(3):146-8. PubMed ID: 8807462
    [No Abstract]   [Full Text] [Related]  

  • 14. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical inquiries. Does screening for microalbuminuria in diabetes prevent complications?
    Hale WA; Nashelsky J; Wilson SA
    J Fam Pract; 2003 Mar; 52(3):229-31. PubMed ID: 12620179
    [No Abstract]   [Full Text] [Related]  

  • 16. Should Angiotensin converting enzyme inhibitors be used in children with type 1 diabetes and microalbuminuria?
    Almerie MQ; Williams RM; Acerini CL
    Arch Dis Child; 2008 Jul; 93(7):633-5. PubMed ID: 18285389
    [No Abstract]   [Full Text] [Related]  

  • 17. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
    Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
    CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for microalbuminuria.
    Peterson KA
    J Fam Pract; 2001 Aug; 50(8):674-5. PubMed ID: 11509160
    [No Abstract]   [Full Text] [Related]  

  • 20. [Albuminuria in the diabetic patient: clinical relevance and methodological features].
    Clerico A; Penno G; Giampietro O
    Minerva Endocrinol; 1991; 16(4):157-61. PubMed ID: 1815116
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.